Related Experiment Video

Updated: Oct 15, 2025

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.1K

Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study

Asghar Abdoli1,2, Reza Aalizadeh3, Hossein Aminianfar4

  • 1Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.

Reviews in Medical Virology
|October 26, 2021
PubMed

Insights

The BIV1-CovIran vaccine, an inactivated whole-virus candidate, demonstrated safety and potency against SARS-CoV-2 in animal studies. It successfully induced high levels of neutralizing antibodies and protected rhesus macaques from infection.

Area of Science:

  • Virology
  • Vaccinology
  • Immunology

Background:

  • The COVID-19 pandemic necessitates the development of safe and effective vaccines.
  • Controlling SARS-CoV-2 transmission requires robust vaccine candidates.

Purpose of the Study:

  • To develop an inactivated whole-virus SARS-CoV-2 vaccine candidate, BIV1-CovIran.
  • To evaluate the safety and potency of the BIV1-CovIran vaccine in animal models.

Main Methods:

  • SARS-CoV-2 was isolated, propagated in Vero cells, chemically inactivated, and purified.
  • The vaccine was formulated with alum adjuvant and tested for toxicity and immunogenicity in guinea pigs, rabbits, mice, and monkeys.
  • Rhesus macaques received two doses and were challenged with SARS-CoV-2.

Main Results:

  • BIV1-CovIran showed a favorable safety profile across all tested animal species.
  • Immunization with 3 or 5 μg doses induced significant SARS-CoV-2 specific and neutralizing antibodies in mice, rabbits, and nonhuman primates.
  • Vaccinated rhesus macaques exhibited high protection against a SARS-CoV-2 intratracheal challenge.

Conclusions:

  • BIV1-CovIran is a promising vaccine candidate with the potential to elicit a strong immune response.
  • The inactivated whole-virus vaccine demonstrated feasibility and efficacy in preclinical evaluations.
  • Further development of BIV1-CovIran could contribute to global COVID-19 control efforts.
Keywords:
BIV1-CovIranCOVID-19SARS-CoV-2immunisationinactivated vaccine

More Related Videos

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

12.8K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

2.0K

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.2K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
20
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
22
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
21
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
21